Background
==========

Particulate matter (PM) is a complex mixture of small particles and liquid droplets that contains a number of components, including acids, organic chemicals, metals, and soil or dust particles. PM exposure is known to increase overall mortality and morbidity, mainly due to its effect on the cardiorespiratory system ([@r2]; [@r63]). Exposure to PM may disturb normal physiological pathways that maintain homeostasis and this may activate cellular processes that mediate the adverse effects of PM ([@r37]). Gene expression changes play an important role in the activation of pathways of toxicity and gene signatures have the potential to serve as biomarkers of exposure ([@r72]; [@r70]) and recent reports demonstrate their potential use as biomarkers of effect ([@r39]; [@r18]). As it has been shown previously that transcriptomic responses to diverse environmental stimuli (i.e., chemical exposure, smoking) can be significantly different between men and women ([@r14]; [@r60]), we have opted to perform a sex-specific analysis.

Several studies have suggested that elevated oxidative stress may mediate toxic effects of air pollutants ([@r16]; [@r55]). The systemic inflammatory response following acute inhalation exposure to PM can induce leukocytosis and monocyte release from the bone marrow ([@r20]). Controlled exposure studies of recent diesel exhaust exposure ([@r62]) and recent exposure to ultra-fine particles ([@r27]) have reported evidence of altered gene expression in leukocytes but, to our knowledge, associations between patterns of gene expression and long-term particulate air pollution have not been studied in general populations.

Materials and Methods
=====================

Study Design
------------

As our goal was to identify transcriptomic biomarkers of exposure and effect in a healthy adult population, we started by applying microarray analysis in a discovery cohort of 98 adults for which we modelled particulate matter exposure. On the resulting dataset containing significantly modulated genes and pathways, we applied a literature and bio-informatics approach to identify potential exposure effect biomarkers. Subsequently, these were validated using qPCR analysis in an independent cohort with similar characteristics as the discovery population ([Figure 1](#f1){ref-type="fig"}). Study protocols for the discovery and validation cohort were approved by the Institutional Review Board and the Ethical Committee of Antwerp University and informed consent was obtained from all participants.

![Schematic representation of the application of the modified version of the meet-in-the-middle approach to identify biomarkers of disease. Note: CeVD, cerebrovascular disease; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease.](EHP370.g001){#f1}

Study Population
----------------

***Discovery cohort.*** The original study population was described previously ([@r72]) and consisted of 398 participants from eight different regions of residence in Flanders (Belgium), as part of the first Flemish Environment and Health Survey (FLEHS I) during the period 2001--2006. Participants were recruited in several communities based on random sampling. Inclusion criteria were age 50--65 years, living in Flanders \> 5 years, and being able to complete questionnaires in Dutch. Prior to blood collection, informed consent was obtained from all individuals. A subset of 98 samples was selected for microarray analysis based on previously measured exposure levels to several pollutants including cadmium, lead, polychlorinated biphenyls (PCBs) (138, 153, and 180), dioxins, polycyclic aromatic hydrocarbons (PAHs), and benzene. The overall exposure to these pollutants was estimated using a *z*-score for each pollutant, and study participants with both low- and high- exposure levels were chosen for inclusion. *Z*-scores were not correlated with long-term PM~10~ exposure (*r* ^2^ = 0.0012). Smokers were excluded from the study population. PAXgene tubes (PreAnalytiX GmbH, Hombrechtikon, Switzerland) were used for RNA collection.

***Validation cohort.*** The quantitative polymerase chain reaction (qPCR) validation study was performed in an independent cohort of 175 adults who were part of the third Flemish Environment and Health Survey (FLEHS III) during the period 2012--2015. Healthy volunteers who were between 50 and 65 years of age, living at the same residential address for at least 10 years, and able to complete questionnaires in Dutch were recruited through registers of general medical practices. Prior to blood collection, informed consent was obtained from all individuals. Participants completed a questionnaire covering age, sex, and smoking habits, among other demographic characteristics; they donated blood and urine samples; and subclinical measurements including height, weight, and blood pressure were determined. The sampling campaign lasted from May 2014 until 30 December 2014. We used PAXgene tubes (PreAnalytiX GmbH, Hombrechtikon, Switzerland) to stabilize whole blood RNA for storage.

Exposure Estimates
------------------

The PM~10~ and PM~2.5~ (10 and 2.5 μm in aerodynamic diameter) concentrations for participants' residential addresses were calculated using a spatial temporal interpolation method (Kriging) that takes into account land cover data from satellite images \[CORINE (coordination of information on the environment) land cover data set; <http://www.eea.europa.eu/publications/COR0-landcover>\] for interpolating the measurement data of the monitoring stations from the Belgian telemetric air quality network as described previously ([@r49]; [@r31]; [@r33]). Validation statistics of the interpolation tool gave a temporal explained variance of \> 0.7 for hourly PM~10~ averages as well as for annual mean PM~10~ ([@r49]). In combination with the Immission Frequency Distribution Model (IFDM)\] using emissions from line sources and point sources, the model chain provides daily PM~10~ and PM~2.5~ values on a 25 × 25 m receptor grid ([@r40]). Our model is based on input data from 38 monitoring stations in the study area. The Initiative on Harmonisation within Atmospheric Dispersion Modelling for Regulatory Use in Europe was the incentive for intensive model intercomparison. IFDM was thoroughly compared with other models currently in use for regulatory purposes in Europe ([@r58]; [@r46]; [@r11], [@r12]; [@r51]).

Mean daily temperatures and relative humidity for the study region were provided by the Royal Meteorological Institute (Brussels, Belgium), and apparent temperature was calculated ([@r68]; [@r35]).

All our estimates were annual mean exposures over a 2-year period because we were interested in developing biomarkers for long-term exposure. For the discovery cohort, annual means were based on 2011--2012 as these were the earliest years for which detailed 25 × 25 m grid information became available. Distribution patterns were used for the year 2008. We assumed that relative differences in annual mean concentrations of particulate matter were generally consistent from year to year. For the validation cohort, annual means were based on the 2 years prior to blood sampling (i.e., 2012--2013).

RNA Isolation
-------------

Total RNA was isolated from 2.5 mL whole blood from PAXgene Blood RNA vacutainers using the PAXgene Blood RNA system (PreAnalytiX, Qiagen, Hilden, Germany), according to the manufacturer's instructions. A globin reduction assay (GLOBINclear™ Kit by Ambion, Austin, TX, USA) was performed in order to remove hemoglobin mRNA from samples that were submitted to microarray analysis. RNA integrity was assessed using the BioAnalyzer (Agilent, Palo Alto, CA, USA) and purity was measured spectrophotometrically. Labeled samples were checked for specific activity and dye incorporation.

Microarray Preparation and Hybridization
----------------------------------------

We used 0.2 μg total RNA from each sample to synthesize dye-labeled cRNA (Cy3) following the Agilent one-color Quick-Amp labeling protocol (Agilent Technologies). Individual samples were hybridized on Agilent 4 × 44 K Whole Human Genome microarrays (design ID 014850).

Microarray Data Analysis
------------------------

Microarrays were scanned on an Agilent G2505C DNA Microarray Scanner (Agilent Technologies, Amstelveen, Netherlands). Raw data on pixel intensities were extracted from the scanned images using Agilent Feature Extraction Software (version 10.7.3.1; Agilent Technologies, Amstelveen, Netherlands), protocol GE1_107.sep09. Raw data were pre-processed using an in-house developed quality control pipeline in R (version 2.15.3; R Project for Statistical Computing) as follows: local background correction, flagging of bad spots, controls and spots with intensities below background, log2 transformation and quantile normalization. The R-scripts of the pipeline and additional information on the flagging can be found at <https://github.com/BiGCAT-UM/arrayQC_Module>. From the processed data files genes were omitted showing more than 30% flagged data, after which the data files were transferred to the Gene Expression Pattern Analysis Suite, GEPAS 2010 ([@r54]) for further preprocessing, including merging replicate probes (based on median), and imputing missing values by means of K-nearest neighbor imputation (K = 15). Filtering for flat peaks was used with root mean square value 0.25. The filtered data, containing 28,786 genes, were used for further statistical analyses. Microarray gene expression data were analyzed and stratified for sex. In the original microarray data that set initially 28,786 unique Agilent probe IDs (out of 43,376 Agilent probe IDs) were annotated to 22,390 EntrezGene IDs. In case of multiple replicates (i.e., multiple probes for the same gene), the replicate with highest interquartile range (IQR) in relative gene expression was selected. This resulted in 15,589 unique EntrezGene IDs.

Gene Expression Analysis
------------------------

Using linear regression models adjusted for age, body mass index (BMI), socioeconomic status (SES, classified in three groups: no high school degree, high school degree, or further education degree), daytime and season of blood sampling, we obtained estimates for each gene as the log~2~-fold change in gene expression for an increment of 5 μg/m^3^ in exposure. *p*-Values \< 0.05 were considered statistically significant. *p*-Values were corrected for multiplicity using the Benjamini--Hochberg false discovery rate (FDR) correction. *p*-Values corrected for multiple testing are referred to as *q*-values.

Pathway Analysis
----------------

Gene Set Enrichment Analysis was performed utilizing the online pathway analysis tool Consensus Pathway Data Base (CPDB) (<http://consensuspathdb.org/>). CPDB contains \~ 5,200 pathways including protein complexes, metabolic, signaling, and gene regulatory pathways, as well as drug-target interactions. Data originate from 32 public resources curated from the literature ([@r36]). Gene Set Enrichment Analysis was performed in a sex-specific manner using the log~2~-fold changes of the gene expression data for all genes analyzed at the gene expression level, without preselection. For every predefined gene set in each pathway, a Wilcoxon signed-rank test was calculated, testing the null hypothesis that the distribution of their fold changes was around zero. As input, all genes without *a priori* selection (EntrezGene IDs) were uploaded with their fold changes in their gene expression. We selected the biological processes using pathways as output. The *p*-values were corrected for multiplicity and were presented as *q*-values. We defined significant biological processes and pathways by a threshold on the adjusted *p*-value (*q* \< 0.05 or FDR 5%) and we included gene sets with a size between 5 and 100 members.

Selection of Potential Exposure/Effect Biomarker Genes
------------------------------------------------------

We used a modified version of the meet-in-the-middle approach for biomarker identification in relation to clinical relevance ([@r73]), a schematic representation is shown in [Figure 1](#f1){ref-type="fig"}. We first identified the top 50 genes associated with PM~10~ (i.e., with the smallest uncorrected *p*-values) in men and women, respectively, then performed a literature search using PubMed and ScienceDirect to identify genes within each sex-specific set that have been associated with air pollution-related health outcomes. Specifically, we searched for the name of each gene in combination with any of the following diseases or processes: allergy ([@r48]), chronic obstructive pulmonary disease (COPD) ([@r38]), asthma ([@r4]), lung cancer ([@r64]), cardiovascular disease (CVD) ([@r52]), cerebrovascular disease (CeVD) ([@r34]), Alzheimer's disease ([@r19]) and cognition ([@r13]). Genes with lowest *p*-values and proven link to air pollution (AP)-related diseases were chosen for validation. For men, *DNAJB5*, *RAC3*, *EAPP*, *HDLBP*, *PRG2*, *PER1*, *PIK3R1*, and *SLA2* were selected for validation, whereas for women the gene list for validation included *AKAP6, LIMK1, SIRT7, ARHPGAP4, ATG16L2, TPM3, 5-HTR1B*, and *PYGO2*.

Validation of Candidate Biomarker Genes by qPCR
-----------------------------------------------

***qPCR.*** Total RNA was reverse transcribed into cDNA by means of the GoScript Reverse Transcription System (Promega, Madison, WI, USA) using a Veriti 96 well Thermal cycler (TC-5000, Techne, Burlington, NJ, USA). A maximum of 3 μg of total RNA was used as input, and we used the protocol with an equal amount of oligo(dT) and random hexamer primers according to the manufacturer's instructions. cDNA was stored at --20°C until further measurements. A quantitative real-time polymerase chain reaction (qPCR) was set up by adding 2 μL of a 10 ng/μL dilution of cDNA together with TaqMan Fast Advanced Master Mix (Life Technologies, Foster City, CA, USA) and PrimeTime^TM^ assay (Integrated DNA Technologies, Coralville, IA, USA), in a final reaction volume of 10 μL. Standard cycling conditions were used to analyze samples in a 7900HT Fast Real-Time PCR system (Life Technologies, Foster City, CA, USA). Expression of eight candidate biomarker genes for each sex was studied and Cq values were collected with SDS 2.3 software. Minimum Information on qPCR Experiments (MIQE) guidelines were taken into account ([@r7]). Amplification efficiencies were between 90% and 110% for all assays. Raw data were processed to normalized relative gene expression values with qBase plus (Biogazelle, Zwijnaarde, Belgium) ([@r22]). Triplicates were run for all samples; technical replicates were included when the difference in Cq value was \< 0.5. A set of three genes was used for data normalization, namely Hypoxanthine Phosphoribosyltransferase 1 (*HPRT*), Importine 8 (*IPO8*) and tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta (*YWHAZ*).

***Data analysis.*** Statistical analyses were carried out using SAS software (version 9.3, SAS Institute Inc., Cary, NC, USA). Continuous data were presented as mean ± standard deviation (SD) and categorical data as percentages (%) and frequencies. Models were adjusted for age, body mass index (BMI), SES, smoking (categorized as smokers, former smokers and never smokers), white blood cell counts (absolute number of leukocytes and percentage of neutrophils), time of day (\< 1200 hours, 1200--1500 hours, 1500--1800 hours, \> 2000 hours) and season (October--March or April--September) of blood sampling. *p*-Values \< 0.05 were considered statistically significant, *p*-values corrected for multiple testing referred to as *q*-values. We plotted residuals for each gene to check whether significance was driven by outliers, these were removed where appropriate. To indicate significance of selected biomarker genes for each sex, we included an interaction term for sex in our main analysis. *p*-Values for the interaction term sex were calculated for all genes under study, not only those that were significant.

In validation analysis, we examined the association between gene expression and PM~10~ exposure, stratified by sex using linear regression models for the eight selected genes for each sex.

ROC Curves Exposure Prediction
------------------------------

We calculated the ability to predict PM~10~ exposure based on expression of the set of eight validated genes significantly associated with PM~10~ exposure in the discovery cohort for each sex. For this purpose, we estimated sensitivity and specificity of the prediction using receiver operating characteristic (ROC) plots. Subjects were stratified according to their long-term PM~10~ exposure levels with the 75th percentile as cut-off point (25.7 μg/m^3^ annual mean for women, 24.5 μg/m^3^ for men). All analyses were repeated similarly using long-term PM~2.5~ exposure levels, the cut-off point for long-term PM~2.5~ exposure, or the 75th percentile of exposure was 16.0 μg/m^3^ for both men and women.

Results
=======

Population Characteristics
--------------------------

[Table 1](#t1){ref-type="table"} lists the characteristics of the study cohorts. All participants were of European origin. Distribution of sex, SES, age and BMI as well as exposure did not differ between the discovery and validation cohort. Both cohorts included just less than 50% men and age averaged (SD) 57.9 (4.3) years. Season of sampling differed between both cohorts, with sampling for the discovery phase of the study mainly occurring throughout the warm months of the year, whereas sampling for the validation study was mainly performed during the cold season. However, since we are working with average annual exposures over a 2-year period, this approach in itself corrects for the differences across seasons. Blood sampling was done ≤ 1500 hours for all discovery cohort participants, while most validation cohort participants had samples drawn after 1500 hours. The discovery cohort consistent only of non-smokers, whereas the validation cohort included smokers (*n* = 21).

###### 

Study population and exposure characteristics.

  Characteristics                                                                                                                     Discovery cohort Men (*n* = 48)   Validation cohort Men (*n* = 75)   Discovery cohort Women (*n* = 50)   Validation cohort Women (*n* = 94)
  ----------------------------------------------------------------------------------------------------------------------------------- --------------------------------- ---------------------------------- ----------------------------------- ------------------------------------
  Age, years                                                                                                                          58.0 ± 4.5                        58.0 ± 4.1                         57.8 ± 4.2                          58.1 ± 4.0
  Body mass index, kg/m^2^                                                                                                            27.4 ± 3.5                        26.1 ± 3.8                         25.8 ± 3.7                          25.5 ± 4.7
  Socioeconomic status                                                                                                                                                                                                                         
  Low                                                                                                                                 20 (41.7)                         14 (18.7)                          28 (56.0)                           23 (24.5)
  Medium                                                                                                                              15 (31.3)                         26 (34.7)                          7 (14.0)                            16 (17.0)
  High                                                                                                                                13 (27.1)                         35 (46.7)                          15 (30.0)                           55 (58.5)
  Smoking status                                                                                                                                                                                                                               
  Nonsmokers                                                                                                                          48 (100.0)                        25 (33.3)                          50 (100.0)                          49 (52.1)
  Former smoker                                                                                                                       NA                                43 (57.3)                          NA                                  31 (33)
  Current smoker                                                                                                                      NA                                7 (9.3)                            NA                                  14 (14.9)
  Season of blood sampling                                                                                                                                                                                                                     
  Cold (October--March)                                                                                                               40 (83.3)                         27 (36.0)                          40 (80.0)                           40 (42.6))
  Warm (April--September)                                                                                                             8 (16.7)                          48 (64.0)                          10 (20.0)                           54 (57.4))
  Time of blood sampling                                                                                                                                                                                                                       
  \< 1200 hours                                                                                                                       41 (85.4)                         0 (0.0)                            44 (88.0)                           7 (7.5)
  1200--1500 hours                                                                                                                    7 (14.6)                          20 (26.7)                          6 (12.0)                            25 (26.6)
  1500--1800 hours                                                                                                                    0 (0.0)                           32 (42.7)                          0 (0.0)                             43 (45.7)
  \> 2000 hours                                                                                                                       0 (0.0)                           23 (30.7)                          0 (0.0)                             19 (20.2)
  White blood cell count                                                                                                                                                                                                                       
  Leukocytes (\#/μL)                                                                                                                  ---                               6981.5 ± 1632.1                    ---                                 6981.5 ± 1632.1
  Neutrophils (%)                                                                                                                     ---                               56.8 ± 8.1                         ---                                 56.8 ± 8.1
  Exposure (μg/m^3^)                                                                                                                                                                                                                           
  PM~10~ long-term                                                                                                                    25.8 (21.5--30.4)                 23.1 (20.3--27.4)                  26.0 (20.5--35.3)                   24.2 (20.4--28.2)
  PM~2.5~ long-term                                                                                                                   17.7 (15.5--20.8)                 15.5 (14.5--17.6)                  17.8 (15.4--20.9)                   16.0 (14.7--18.3)
  Note: Data are mean ± SE or number (%), exposure data are mean (5--95th percentile). ---, data not available; NA, not applicable.                                                                                                            

Gene Level Analysis
-------------------

[Table 2](#t2){ref-type="table"} displays the 20 top genes for PM~10~ and PM~2.5~ exposure in men and women. Excel File Tables S1--S4 display the extended top 50 lists for each exposure/sex combination. An overview on the total number of significant genes identified in our analysis, indicating the overlap between men and women, is given in [Figure 2](#f2){ref-type="fig"}. For 199 gene transcripts we noticed significant sex by particulate matter exposure (PM~10~) interactions (data not shown). The corresponding number of gene transcripts for PM~2.5~ with a significant sex by exposure interaction was 601 (data not shown). In men, there were significant associations between 47 genes and PM~10~ only, 149 genes and PM~2.5~ only, and there were 92 genes associated with both exposures. In women there were significant associations between 91 genes and PM~10~ only, 1,067 genes and PM~2.5~ only, and there were 498 genes associated with both exposures. We identified two genes in common between long-term PM~10~ exposure in men and women, namely *RAC3* and *DNAJB5*, respectively ranked as the 290th and 331st most significant genes with PM~10~ exposure in women (out of 592 genes). Furthermore *RAC3* was also significantly associated with long-term PM~2.5~ exposure in men and *DNAJB5* with long-term PM~2.5~ exposure in women. We did not observe any significant FDR-corrected *q*-values in the discovery phase of our study.

###### 

Top 20 significant genes in association with 5-μg/m^3^ increase in long-term PM~10~ and PM~2.5~ exposure for men and women.

  Rank no. gene                                                                                                                                                                                                       Men          Women                                                                                            
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------ ------------------- ----------- ------------------- ------------ ------------------- ----------- -------------------
  *1*                                                                                                                                                                                                                 *EAPP*       1.15 (1.07, 1.24)   *ISL2*      2.45 (1.58, 3.78)   *ATG16L2*    0.81 (0.73, 0.90)   *EFNB1*     0.64 (0.53, 0.77)
  *2*                                                                                                                                                                                                                 *DCTN6*      1.23 (1.10, 1.38)   *HDLBP*     1.31 (1.14, 1.50)   *EFNB1*      0.79 (0.69, 0.89)   *SLC6A7*    1.52 (1.25, 1.86)
  *3*                                                                                                                                                                                                                 *DNAJB5*     1.36 (1.14, 1.63)   *B3GNT3*    1.42 (1.18, 1.70)   *SYTL1*      0.86 (0.79, 0.93)   *FXN*       0.73 (0.62, 0.85)
  *4*                                                                                                                                                                                                                 *ISL2*       1.55 (1.17, 2.06)   *RNF144*    1.83 (1.28, 2.62)   *SMG5*       0.84 (0.76, 0.92)   *SFPQ*      1.41 (1.18, 1.67)
  *5*                                                                                                                                                                                                                 *KIAA1914*   1.23 (1.07, 1.42)   *ATOH8*     2.24 (1.37, 3.66)   *TBC1D10C*   0.85 (0.78, 0.93)   *NACAL*     0.69 (0.58, 0.84)
  *6*                                                                                                                                                                                                                 *HDLBP*      1.14 (1.04, 1.24)   *RAC3*      1.62 (1.21, 2.18)   *NACAL*      0.81 (0.72, 0.91)   *ATG16L2*   0.72 (0.61, 0.86)
  *7*                                                                                                                                                                                                                 *B3GNT3*     1.19 (1.06, 1.34)   *ADCK1*     1.49 (1.17, 1.91)   *NFKBIE*     0.85 (0.78, 0.93)   *SLC24A2*   1.73 (1.28, 2.32)
  *8*                                                                                                                                                                                                                 *ATOH8*      1.55 (1.14, 2.10)   *DNAJB5*    1.62 (1.20, 2.18)   *CEMP1*      0.80 (0.70, 0.91)   *THEX1*     0.34 (0.19, 0.62)
  *9*                                                                                                                                                                                                                 *LSM12*      0.86 (0.77, 0.95)   *ALX3*      1.40 (1.13, 1.73)   *DCUN1D2*    0.84 (0.76, 0.93)   *TBC1D13*   0.78 (0.68, 0.90)
  *10*                                                                                                                                                                                                                *ZNF187*     1.16 (1.04, 1.28)   *MAN2A2*    1.39 (1.13, 1.72)   *SLC6A7*     1.25 (1.10, 1.43)   *VAPB*      1.21 (1.09, 1.35)
  *11*                                                                                                                                                                                                                *ARHGAP25*   1.11 (1.03, 1.20)   *DCTN6*     1.35 (1.11, 1.64)   *DHRSX*      1.21 (1.08, 1.36)   *TPM3*      0.44 (0.28, 0.70)
  *12*                                                                                                                                                                                                                *SERF1B*     0.83 (0.72, 0.95)   *DAK*       1.34 (1.10, 1.64)   *TBC1D13*    0.86 (0.79, 0.94)   *CYB5D1*    0.39 (0.23, 0.67)
  *13*                                                                                                                                                                                                                *ANXA1*      1.19 (1.05, 1.36)   *PER1*      1.37 (1.11, 1.69)   *SFPQ*       1.21 (1.08, 1.35)   *ZNF77*     0.61 (0.46, 0.81)
  *14*                                                                                                                                                                                                                *TKTL1*      1.36 (1.09, 1.71)   *GUCA2B*    1.78 (1.20, 2.62)   *MAPK3*      1.19 (1.07, 1.32)   *GABRD*     0.40 (0.24, 0.67)
  *15*                                                                                                                                                                                                                *PRG2*       1.29 (1.07, 1.56)   *ATXN7L3*   1.30 (1.09, 1.55)   *ZFYVE27*    0.91 (0.86, 0.96)   *NFKBIE*    0.78 (0.68, 0.90)
  *16*                                                                                                                                                                                                                *PER1*       1.19 (1.05, 1.36)   *LSM12*     0.77 (0.64, 0.92)   *SLC39A2*    1.32 (1.11, 1.55)   *CEACAM3*   1.67 (1.24, 2.23)
  *17*                                                                                                                                                                                                                *GUCA2B*     1.38 (1.09, 1.75)   *PRG2*      1.57 (1.15, 2.13)   *TSPAN4*     1.37 (1.13, 1.65)   *TSPAN4*    1.69 (1.25, 2.28)
  *18*                                                                                                                                                                                                                *ST14*       1.20 (1.05, 1.37)   *ABL2*      1.40 (1.11, 1.78)   *DNAJC5*     0.87 (0.81, 0.95)   *GPR137*    0.64 (0.50, 0.83)
  *19*                                                                                                                                                                                                                *CDV3*       0.84 (0.73, 0.96)   *MAST3*     1.27 (1.07, 1.49)   *MIA*        0.82 (0.73, 0.93)   *DNAJC5*    0.80 (0.70, 0.91)
  *20*                                                                                                                                                                                                                *TTC30B*     1.20 (1.04, 1.37)   *PIK3R1*    1.46 (1.12, 1.89)   *CES2*       1.16 (1.06, 1.28)   *HSF1*      0.85 (0.77, 0.93)
  Note: Rank no. gene indicates its hierarchy for that particular exposure and sex based on level of significance of the identified association, so gene ranked as no. 1 has the lowest *p*-value. FC, fold change.                                                                                                                 

![Venn diagram showing the overlap of all genes significantly associated with long-term PM~10~ and PM~2.5~ exposure in men and women in the discovery cohort.](EHP370.g002){#f2}

Pathway Analysis
----------------

There were 1,251 and 966 pathways significantly associated with PM~10~ and PM~2.5~, respectively, in men, and 280 and 182 pathways significantly associated with PM~10~ and PM~2.5~ in women, based on uncorrected *p*-values. The top 5 identified pathways for each indicator of exposure are summarized in [Table 3](#t3){ref-type="table"}.

###### 

The top five significant pathways defined by gene set enrichment analysis for each indicator of exposure.

  Exposure/pathway                                                                                                                                                   *q*‑Value   \# measured/\# genes in pathway
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------- ---------------------------------
  Men                                                                                                                                                                            
  PM~10~                                                                                                                                                                         
  Response to elevated platelet cytosolic Ca2+                                                                                                                       3·11E-07    76/87
  Prolactin signaling pathway                                                                                                                                        5·78E-07    61/72
  Platelet degranulation                                                                                                                                             5·90E-07    71/82
  Leukocyte transendothelial migration                                                                                                                               1·25E-06    98/118
  Signaling by insulin receptor                                                                                                                                      5‑18E‑06    89/109
  PM~2.5~                                                                                                                                                                        
  Cell-cell communication                                                                                                                                            1·35E-08    95/130
  Chagas disease (American trypanosomiasis)                                                                                                                          1·40E-06    92/104
  Signaling by type 1 insulin-like growth factor 1 receptor (IGF1R)                                                                                                  1·40E-06    76/96
  Signaling by insulin receptor                                                                                                                                      1·93E-06    96/120
  Insulin receptor signaling cascade                                                                                                                                 2·33E-06    74/76
  Women                                                                                                                                                                          
  PM~10~                                                                                                                                                                         
  Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins                                                 2·08E-04    89/97
  Packaging of telomere ends                                                                                                                                         3·98E-04    46/53
  Electron transport chain                                                                                                                                           8·11E-04    94/103
  Respiratory electron transport                                                                                                                                     9·59E-04    71/76
  Telomere maintenance                                                                                                                                               1·50E-03    72/81
  PM~2.5~                                                                                                                                                                        
  Respiratory electron transport                                                                                                                                     9·07E-04    81/92
  Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins                                                 1·77E-03    99/113
  Packaging of telomere ends                                                                                                                                         4·54E-03    45/52
  Proteasome                                                                                                                                                         4·93E-03    41/44
  Transcriptional regulation by small RNAs                                                                                                                           4·93E-03    95/106
  Note: Pathways were identified using the Gene Set Enrichment Analysis Tool from the online Consensus Pathway Data Base (http://cpdb.molgen.mpg.de/). \#, number.               

Long-term PM~10~ exposure in men is associated with response to elevated platelet cytosolic Ca^2+^, the prolactin signaling pathway and platelet degranulation. The 5th top significant pathway in association with PM~10~ exposure in men is signaling by insulin receptor, which ranks 4th when analyzing long-term PM~2.5~ exposure. Other pathways associated with PM~2.5~ exposure in men are cell-cell communication and signaling by Type 1 Insulin-like Growth Factor and Insulin receptor signaling cascade. For women, long-term PM~10~ exposure was associated with, in descending order of significance, respiratory electron transport, packaging of telomere ends, electron transport chain, respiratory electron transport and telomere maintenance. PM~2.5~ exposure was associated with respiratory electron transport, and the proteasome in women ([Table 3](#t3){ref-type="table"}).

Transcriptome Signature in Relation to Long-Term Exposure
---------------------------------------------------------

We selected eight genes that were significantly (*p* \< 0.05) associated with long-term PM~10~ exposure in the microarray study and have a published link with air pollution-related disease ([Table 4](#t4){ref-type="table"}) for validation in an independent cohort. Of these we could confirm (i.e., they were also significantly associated with PM~10~ in the validation cohort based on uncorrected *p*-values, and associations were in the same direction as in the discovery cohort) two out of eight genes for men \[DnaJ homolog, subfamily B, member 5 (*DNAJB5*), and E2F associated phosphoprotein (*EAPP*)\] and one out of eight genes for women to be \[Rho GTPase Activating protein 4 (*ARHGAP4*)\] borderline significantly (*p* = 0.0535) associated with PM~10~ exposure ([Table 4](#t4){ref-type="table"}). *AKAP6* (*p* = 0.02) and *LIMK1* (*p* = 0.006) were significantly associated with PM~10~ in women in the validation cohort, albeit with significantly lower expression instead of higher expression as in the discovery cohort. We also tested the same sets of eight genes for each sex for associations with PM~2.5~ exposure in the validation cohort, since all but one of the candidate genes (*PYG02* in women, which also was not significant for PM~10~ in the discovery cohort) were significantly associated with long-term PM~2.5~ exposure in the discovery cohort. For PM~2.5~ exposure, we could confirm two out of eight genes \[*DNAJB5* (borderline significant, *p* = 0.059) and *EAPP*\] for men and four out of eight genes for women \[*ARHGAP4*, *PYGO2*, sirtuin 7 (*SIRT7*) and Autophagy related 16-like 2 (*ATG16L2*)\] (see Table S1). Excluding 21 current smokers (14 of 94 women and 7 of 75 men) from the validation cohort did not alter our conclusions, based on the similarity in the effect estimates, apart from expression of *ARHGAP4* in association with long-term PM~10~ exposure (see Table S2).

###### 

Selection of biomarker candidate genes and their fold changes for an increase of 5 μg/m^3^ long-term PM~10~ exposure.

  Gene name                                                                                                                                                                                                              Gene description                                                                          Gene function                                                       Link to disease                                                     Discovery cohort FC (95% CI)   *p*-Value   Validation cohort FC (95% CI)   *p*-Value   *q*-Value
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- ------------------------------------------------------------------- ------------------------------------------------------------------- ------------------------------ ----------- ------------------------------- ----------- -----------
  Men                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  *DNAJB5*                                                                                                                                                                                                               DnaJ (Hsp40) homolog, subfamily B, member 5                                               Heat shock protein 40                                               CVD (Ago et al. 2008)                                               1.36 (1.14, 1.63)              0.0014      1.64 (1.20, 2.23)               0.0026      0.02
  *RAC3*                                                                                                                                                                                                                 Ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3)   Regulation of cellular responses (cell growth)                      Lung cancer (Liu et al. 2015)                                       1.25 (1.04, 1.51)              0.024       1.26 (0.94, 1.96)               0.10        0.18
  *EAPP*                                                                                                                                                                                                                 E2F associated phosphoprotein                                                             Cell cycle/apoptosis                                                Lung cancer (DeMuth et al. 1998)                                    1.15 (1.0, 1.24)               0.00055     1.18 (1.02, 1.38)               0.028       0.12
  *HDLBP*                                                                                                                                                                                                                High density lipoprotein binding protein (vigilin)                                        Sterol metabolism                                                   CVD (Husten 1998)                                                   1.14 (1.04, 1.24)              0.0065      1.02 (0.88, 1.19)               0.75        0.86
  *PRG2*                                                                                                                                                                                                                 Proteoglycan 2                                                                            Eosinophil major basic protein                                      CVD (Melchior et al. 2013), asthma (Li et al. 2006)                 1.29 (1.07, 1.56)              0.012       1\. 29 (0.98, 1.71)             0.066       0.18
  *PER1*                                                                                                                                                                                                                 Period homolog 1 (Drosophila)                                                             Circadian rhythm                                                    CVD (Young et al. 2001)                                             1.19 (1.05, 1.36)              0.012       0.95 (0.74, 1.23)               0.72        0.86
  *PIK3R1*                                                                                                                                                                                                               Phosphoinositide-3-kinase, regulatory subunit 1 (p85 alpha)                               Insulin metabolism                                                  Lung cancer (Lu et al. 2006)                                        1.22 (1.03, 1.43)              0.023       1.01 (0.82, 1.26)               0.91        0.91
  *SLA2*                                                                                                                                                                                                                 Src-like adaptor 2                                                                        SLAP adapter protein                                                CVD (Cherpokova et al. 2015)                                        1.22 (1.03, 1.44)              0.027       1.16 (0.97, 1.39)               0.11        0.18
  Women                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  *AKAP6*                                                                                                                                                                                                                A kinase (PRKA) anchor protein 6                                                          Regulatory subunit of protein kinase A                              CVD (Oti et al. 2006)                                               1.21 (1.07, 1.36)              0.0036      0.72 (0.55--0.94)               0.017       0.05
  *LIMK1*                                                                                                                                                                                                                LIM domain kinase 1                                                                       Regulation of actin filament dynamics                               Lung cancer (Chen et al. 2013), Alzheimer's (Heredia et al. 2006)   1.28 (1.06, 1.55)              0.01        0.75 (0.61--0.91)               0.0057      0.03
  *SIRT7*                                                                                                                                                                                                                Sirtuin (silent mating type information regulation 2 homolog) 7 (S. cerevisiae)           Transcription repressor                                             CVD (Vakhrusheva et al. 2008)                                       0.89 (0.82, 0.96)              0.0038      0.80 (0.6--1.07)                0.14        0.22
  *ARHGAP4*                                                                                                                                                                                                              Rho GTPase Activating protein 4                                                           Regulation of small GTP-binding proteins from the RAS superfamily   Cognition (Huang et al. 2012)                                       0.88 (0.81, 0.95)              0.0035      0.62 (0.38--1.00)               0.054       0.11
  *ATG16L2*                                                                                                                                                                                                              Autophagy related 16-like 2 (S. cerevisiae)                                               Autophagy                                                           CVD (Magné et al. 2015)                                             0.81 (0.73, 0.90)              0.00028     0.81 (0.59--1.11)               0.19        0.25
  *TPM3*                                                                                                                                                                                                                 Tropomyosin 3                                                                             Actin-binding protein                                               Lung cancer (Rostila et al. 2012)                                   0.65 (0.48, 0.88)              0.0086      1.02 (0.83--1.26)               0.85        0.85
  *5-HTR1B*                                                                                                                                                                                                              5-Hydroxytryptamine (serotonin) receptor 1B                                               Neurotransmitter/ vasoconstriction                                  CVD (Iwabayashi et al. 2012)                                        1.31 (1.08, 1.59)              0.0097      1.28 (0.49--3.34)               0.62        0.71
  *PYGO2*                                                                                                                                                                                                                Pygophus homolog 2                                                                        Related to Wnt signaling                                            Lung cancer (Liu et al. 2013)                                       0.93 (0.85, 1.01)              0.097       0.75 (0.61--0.92)               0.0078      0.03
  Note: Models adjusted for age, BMI, SES, smoking (validation cohort), leukocyte and neutrophil count, daytime of blood sampling and season. *p*-Values corrected for multiple testing are represented as *q*-values.                                                                                                                                                                                                                                                                                                                            

Validation Set
--------------

To determine whether gene expression candidate biomarkers identified in the discovery cohort were robust exposure markers, we performed ROC curve analysis with long-term PM~10~ exposure level 24.5 μg/m^3^ (75th percentile) as cut-off point in men. [Figure 3A](#f3){ref-type="fig"} shows the sensitivity and 1 minus specificity (false positive ratio) of PM~10~ exposure levels for men in association with the candidate biomarker genes. The model including the eight genes in men had an area under the curve (AUC) value of 0.92 \[95% confidence interval (CI): 0.85, 1.00; *p* = 0.0002\]. In women the model including the eight genes had an AUC of 0.86 (95% CI: 0.76, 0.96; *p* = 0.004) ([Figure 3B](#f3){ref-type="fig"}, cut-off point 25.7 μg/m^3^). The combined gene set perfomed better both in men and women than the individual genes. Similarly, for PM~2.5~ exposure prediction, the model for men had an AUC of 0.91 (95% CI: 0.83, 0.97; *p* = 0.007) ([Figure 3C](#f3){ref-type="fig"}), the model for women had an AUC of 0.90 (95% CI: 0.81, 0.98; *p* = 0.0002) ([Figure 3D](#f3){ref-type="fig"}).

![Receiver operating characteristics (ROC) curve for leukocyte gene expression of gene sets distinguishing between high and low long-term PM~10~ or PM~2.5~ exposure, respectively, based on the eight genes selected for validation for each sex. (*A*) performance of gene set consisting of *DNAJB5*, *RAC3*, *SLA2*,*HDLBP*,*PRG2*,*PER1*,*PIK3R1*, and *EAPP* to dinstinguish between high and low PM~10~ exposure in men (above 75th percentile corresponding to 24.5 μg/m^3^) and low (\< 24.5 μg/m^3^) and (*B*) performance of gene set consisting of *ARHGAP4*, *AKAP6, PYGO2, HTR1B, ATG16L2, SIRT7*,*TPM3* and *LIMK1* in women to distinguish between high (above 75th percentile corresponding to: 25.7 μg/m^3^) and low (\< 25.7 μg/m^3^) long-term residential PM~10~ exposure. (*C*) Performance of same male-specific gene set in men and (*D*) female-specific gene set in women to distinguish between high (above 75th percentile corresponding to: 16.0 μg/m^3^) and low (\< 16.0 μg/m^3^) long-term residential PM~2.5~ exposure.](EHP370.g003){#f3}

Discussion
==========

We identified and validated transcriptome signatures that are associated with long-term exposure to particulate air pollution in apparently healthy men and women. These sets of eight sex-specific genes were predictive of exposure in the validation cohort, and including all eight genes in one model provided a better prediction than the eight genes individually. We found *DNAJB5* and *EAPP* in men and *ARHGAP4* in women based on a discovery set and a validation analysis to be significantly associated with PM~10~ exposure. Besides *ARHGAP4*, our PM~2.5~-exposure analysis for women identified *PYGO2*, *SIRT7,* and *ATG16L2* as significantly associated with particulate matter exposure. However, we cannot assume these associations indicate causal relations due to the observational nature of our study. ROC analysis revealed excellent separation between individuals with high and low exposure to long-term particulate air pollution using the genes selected for validation. We believe gene expression levels have the potential to be used as biomarkers of exposure and effect with high specificity to link particulate air pollution to its health consequences, as these can be measured at the personal level rather than be obtained through exposure modelling at the population level. Further studies looking at different age and ethnic groups are warranted to explore the capabilities of gene expression levels as predictors in more depth. Longitudinal studies that monitor disease incidence, exposure and gene expression over time would be excellent to provide more insights.

We observed different transcriptomic expression levels in association with particulate air pollution exposure in men and women. Sex-specific differences may be explained by differences in inflammatory responses between men and women. Immunologic differences between men and women have been reported based on gene expression profiles in blood between smokers and nonsmokers, where women seem to have a more specific (involving less extensive pathways) immunologic response to smoking than men ([@r17]). Furthermore, sex-specific associations were also reported for microarray expression profiles in relation to environmental exposure to diverse compounds such as PCBs, dioxin, benzene, and PAHs ([@r14]). The sex-specific associations between PM and gene expression that we observed are in line with previous reports of sex-specific associations with other exposures. As such, prenatal exposure to bisphenol A (BPA) led to differential responses in murine placentae of female and male embryos ([@r29]). Prenatal stress exposure in rats was associated with sex-specific differences in gene expression and behavioral effects in male and female offspring ([@r71]). This study clearly shows the same biological exposure (i.e., prenatal stress) leads to a highly differential response in male and female offspring.

To date, limited human data is available on microarray gene expression profiling in response to air pollution exposure. However, in an attempt to study the effects of *in utero* carcinogenic exposures, gene expression profiles in cord blood from 111 babies participating in the Norwegian BraMat cohort were assessed and correlation analyses of gene expression levels with biomarkers of exposure measured showed variable numbers of significantly correlating genes. Overall, separate analyses for male and female newborns resulted in higher numbers of significantly correlating genes per sex with low overlap of similarly expressed genes between the two sexes, thus indicating a clear sex-specific toxicogenomic response. More specifically, the authors reported only 1 gene in common between girls (39 significant genes) and boys (331 significant genes) for dioxin exposure ([@r25]).

Given evidence of the differential responses to PM exposure both at the gene and pathway levels between men and women, we hypothesize that different pathways could lead to the same disease outcome in both sexes. Recently, it was reported that the same personal exposure (i.e., smoking) could lead to disease in a differential manner in men and women. As such, [@r60] described microarray analysis in smokers and nonsmoking men and women. They utilized a population of 24 middle-aged smoking men (*n* = 12) and women (*n* = 12) and an equal number of nonsmoking controls. The gene set correlated with smoking in men was incapable of separating female smokers from nonsmokers and vice versa. They identified a large number of oncogenic pathway gene sets that were significantly different in female smokers compared with male smokers with Gene Set Enrichment Analysis of microarray data. In addition, functional annotation with Ingenuity Pathway Analysis (IPA) identified smoking-correlated genes associated with biological functions in male and female smokers that are directly relevant to well-known smoking related pathologies. However, these relevant biological functions were overrepresented in female smokers compared with male smokers. Identified pathway categories in women were xenobiotic metabolism signaling, actin metabolism signaling, clathrin-mediated signaling, eicosanoid signaling, thrombin signaling, tight junction signaling, molecular mechanism of cancer, and natural killer cell signaling ([@r60]).

The expression of *ARHGAP4* was borderline significantly associated with long-term PM~10~ exposure in women in the discovery cohort, and borderline significant (*p* = 0.0535) in the validation cohort. *ARHGAP4, SIRT7*, and *ATG16L2* were furthermore significantly associated with long-term PM~2.5~ exposure in women in the discovery cohort and validation cohort.

*ARHGAP4* is a RhoGAP that regulates the cytoskeletal dynamics that control cell motility and axon outgrowth ([@r74]). Pygosus 2 (*PYGO2*) is a component of the Wnt signaling pathway required for β-catenin/T-cell factor (TCF)-dependent transcription and has been shown to be upregulated in lung cancer both *in vitro* in non-small cell lung cancer cell lines and *in vivo* in human primary tumor tissue samples ([@r77]).

*In vitro* experiments using hematopoietic stem cells from sirtuin 7 (*SIRT7*) knockout mice have shown *SIRT7* regulates mitochondrial activity and its inactivation causes reduced quiescence, increased mitochondrial protein folding stress, and compromised regenerative capacity of hematopoietic stem cells ([@r53]; [@r42]). Mitochondrial DNA and function have been shown to be associated with chronic air pollution exposure in populations of newborns ([@r32]) and elderly men ([@r76]), hence NAD-dependent deacetylase SIRT7 might provide insight into a molecular mechanism underlying the mitochondrial damage following air pollution exposure. Autophagy related 16-like 2 (*ATG16L2*) is a core autophagy gene. Previously, we found in newborns epigenetic modifications in the mitochondrial genome, in association with PM~2.5~ exposure during gestation and placental mtDNA content, which could reflect signs of mitophagy and mitochondrial death ([@r32]).

The expression of the genes *DNAJB5* and *EAPP* were significantly associated with PM~10~ air pollution exposure in men, in the discovery cohort, and in the validation cohort. DNAJB5 is a member of the evolutionarily conserved DNAJ/HSP40 family of proteins, which regulate molecular chaperone activity by stimulating ATPase activity ([@r57]). DNAJB5 contains a cysteine-rich domain which renders the protein sensitive to ROS. The protein forms a multiprotein complex together with Trx1 and class II histone deacetylases (HDACs) that functions as a master negative regulator of cardiac hypertrophy ([@r1]). E2F-associated phospho-protein (EAPP) is a nuclear phosphoprotein that interacts with the activating members of the E2F transcription factor family. *In vitro* overexpression of EAPP increased the fraction of G1 cells and led to heightened resistance against DNA damage. EAPP itself becomes upregulated after DNA damage and stimulates the expression of p21 independently of p53 ([@r3]).

In pathway analyses, we identified several respiratory chain related pathways significantly associated with long-term PM~10~ and PM~2.5~ exposure in women. [@r66] reported deregulation of expression of respiratory chain, oxidative phosphorylation, and mitochondrial membrane pathways when comparing gene expression profiles in adult nonsmoking men from a heavily polluted area versus a control region in the Czech Republic across different seasons (winter and summer 2009 and winter 2010).

Although sex-related differences have been observed for different environmental pollutions, to our knowledge, this is the first study on microarray gene expression profiles in association with long-term air pollution exposure among middle-aged men and women.

Our study has strengths and limitations. We did our investigations in two independent cohorts for discovery and validation, using the same exposure modeling and the gold standard qPCR as validation tool ([@r8]). Although sample size for the discovery cohort was limited, we believe validation in an independent cohort based on a reliable method such as qPCR indicates the robustness of our analyses. Our study also has its limitations inherent to the cross-sectional nature of our study. We used 2010--2012 air pollution data to develop our high-resolution exposure models, which we applied to the participants' baseline addresses (2004). Studies in the Netherlands ([@r5]), Italy (Rome) ([@r65]), the United Kingdom ([@r6]), and Canada (Vancouver) ([@r23]) have shown that during periods of about 10 years and longer, existing land use regression models predicted historic spatial contrasts well. The use of a relatively homogenous population limits the potential generalizability of our study to populations with different ages, races and ethnicities, or locations. Lastly, our study design did not allow to control for cell counts in the discovery phase of the study. As cell counts were not performed on the samples for microarray analysis, and there is no good means for imputation of these values for Agilent 4 × 44 K arrays during data analysis, we were not able to control for this.

This is the first time levels of gene expression of candidate genes have been used to accurately predict air pollution exposure levels (PM~10~, PM~2.5~). For this purpose, we have established ROC curves based on the genes selected for validation in an independent cohort and were able to separate low- (\< 75th percentile) from high- (\> 75th percentile) exposed individuals. ROC curves are commonly used to compare the diagnostic performance of two or more tests, as they give a good indication of both the sensitivity and specificity of the studied test ([@r21]). As such, it has been demonstrated that gene expression signatures can predict survival for instance in pancreatic ([@r56]) or non-small cell lung cancer ([@r45]). In 2009, this technique was applied for the first time in an environmental epidemiology setting, showing that specific DNA methylation patterns could accurately predict the relationship between exposure to airborne PAHs and childhood asthma incidence. [@r61] investigated PAH levels in cord blood samples from 20 newborns and replicated the association between PAH levels and candidate region methylation in 56 other newborns from the Columbia Center for Children's Environmental Health (CCCEH) cohort that recruits nonsmoking Dominican and African American women and their children residing in different areas of New York in the United States ([@r61]). However, the application of this approach to the field of gene expression data in association with air pollution exposure is novel.

In ROC curve analysis, an AUC of 0.80 is considered a ROC curve with good separation characteristics, and an AUC of 0.90 is considered excellent, in its ability to distinguish between true and false positives. We have identified sex-specific gene-sets that fulfill these criteria for PM~10~ and PM~2.5~ exposure. However, we must interpret the current set within the context of its limitations inherent to the cross-sectional nature of our study.

Conclusions
===========

In conclusion, microarray analysis has identified different gene-expression levels in response to long-term air pollution in men and women. From gene-level analysis, candidate biomarker genes with a reported link to AP-related disease were selected and validated (i.e., significantly associated with PM exposure with the same direction of regulation of expression) in an independent cohort. For men, we propose *DNAJB5* and *EAPP* as biomarkers of exposure. For women, we identified *ARHGAP4*, *PYGO2*, *SIRT7*, and *ATG16L2* as biomarker genes of exposure. ROC analysis revealed that the genes were able to predict high or low PM~10~ exposure accurately. Prospective studies in other populations are needed to confirm our findings with regard to sex-specific expression of these genes in association with PM exposure. Furthermore, it would be highly relevant to analyze the gene expression of these sex-specific gene-sets in cohorts with higher PM exposure as well as in subjects at different stages of life, including the more vulnerable stages such as early childhood and puberty.
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